Category: Science
TIL Therapy in Melanoma: Where We Stand
By Tanisha Jackson, PhD - MRA Scientific Program Director | 4 April 2023 In Science, Treatment
Despite the incredible progress made to develop new treatment options for melanoma, almost 50% of patients are still not responding to the latest approved therapies. To address this important unmet need for patients with difficult to treat melanoma, clinicians are looking to new strategies including cellular therapy.
Melanoma Clinical Trials to Watch: March 2023
By Cody Barnett, MPH, MRA Senior Director of Communications & Patient Engagement | 27 March 2023 In News, Science, Treatment
Clinical trials, and the patient volunteers who make them possible, are critical to advancing melanoma research. In the Melanoma Clinical Trials to Watch article series, we’ll regularly highlight clinical trials that are currently recruiting patients, have recently shared exciting updates, or are blazing new trails.
The Role of Targeted Therapy in Treating Advanced Melanoma
By Rachel Fischer, Ph.D., Associate Director, Scientific Program & Registry | 20 March 2023 In Science, Treatment
Targeted therapies are an important part of the melanoma treatment arsenal, but where do they fit within the standard of care? Learn more about BRAF mutations, targeted therapy, and areas of future research.
Recordings from MRA's 2023 Patient Forum
16 March 2023 In Allies & Partnerships, Events, Melanoma Stories, News, Policy, Prevention, Science, Treatment
MRA’s 2023 Patient Forum brought together melanoma patients, survivors, advocates, and their loved ones to provide lay-friendly, state-of-the-science education and promote collaboration.
From COVID-19 to Melanoma? The Bright Future of mRNA Vaccines
By Cody Barnett, MPH, MRA Senior Director of Communications & Patient Engagement | 10 February 2023 In Science
Vaccines play an important role in keeping us healthy by protecting us from getting sick or by reducing the severity or duration of an illness. In addition to these preventive vaccines, researchers are also working to develop vaccines that treat disease, including melanoma, known as therapeutic vaccines.
Leading the Charge: MRA 2022 Annual Report
1 February 2023 In Allies & Partnerships, Melanoma Stories, News, Policy, Prevention, Science, Treatment
Since our inception in 2007, the Melanoma Research Alliance (MRA) has been laser-focused on advancing cutting-edge research needed to achieve our mission. With our singular vision, MRA stands as the largest private nonprofit funder of melanoma research in the world.
Nearly 100,000 Americans Estimated to be Diagnosed with Melanoma in 2023
By Joan Levy, PhD - MRA Chief Science Officer | 19 January 2023 In News, Prevention, Science, Treatment
Each January, the American Cancer Society (ACS) releases updated estimates about trends in new cancer cases and deaths in its annual report, Cancer Facts and Figures. This report highlights the estimated incidence (number of new cases), prevalence (number of people alive today with a history of cancer), and survival statistics for cancer in the United States.
Registration Now Open: MRA's 2023 Patient Forum
19 January 2023 In Allies & Partnerships, Events, News, Prevention, Science, Treatment
Registration for MRA's Melanoma Exchange Patient Forum, held in-person in Washington DC and virtually on Wednesday, March 8, is now open. Register now to hear from leading experts in the melanoma field and have the opportunity to ask questions, discuss, and network with other people who are going through their own melanoma journey.
From Melanoma Patient to Caregiver
By Renee Orcione, MRA Digital Engagement & Communications Manager | 11 November 2022 In Allies & Partnerships, Melanoma Stories, Prevention, Science, Treatment
By the time she was 26-years old, Leah Adams had spent countless hours tanning. Growing up in Ohio where the winters were long, she felt a pressure to stay tan far beyond the summer months, so she turned to tanning beds.
FDA Approves Opzulera for At-Home Therapy for Skin Repigmentation: What this Means for Melanoma Patients with Vitiligo
By Isabel Ryan, MRA Intern | 24 October 2022 In News, Science
On July 18th, the U.S. Food & Drug Administration (FDA) approved the first topically-applied treatment for skin repigmentation for patients with vitiligo after strong results from two Phase 3 trials. Vitiligo, a chronic skin disease, affects 3 in 100 people who have melanoma, categorized as melanoma-associated vitiligo. The approval invites patients with vitiligo, including those with melanoma, to talk with their providers on how Opzelura can serve their skin needs.